{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T06:27:13Z","timestamp":1787120833095,"version":"build-2736575974"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Locally advanced non-small-cell lung cancer (LA-NSCLC) is a subtype of lung cancer with substantial heterogeneity in clinical prognosis. Immune injury induced by radiotherapy exposure is a critical factor affecting treatment response and long-term outcomes. This study enrolled patients with LA-NSCLC to investigate the prognostic value of complete blood count (CBC) parameters combined with the estimated dose of radiation to immune cells (EDRIC), aiming to facilitate precision prognostic stratification and tailored treatment strategies in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This study included 329 patients with LA-NSCLC who received radiotherapy (RT) at our institution. Serial CBC measurements were obtained pre-RT, weekly during RT, and 1-month post-RT. EDRIC was calculated based on the model developed by Jin et\u00a0al. and improved by Ladbury et\u00a0al. We subsequently evaluated the associations of EDRIC and CBC parameters with overall survival (OS), local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), and progression-free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Univariate and multivariate analyses demonstrated that EDRIC, together with week 3 platelet-to-lymphocyte ratio (PLR), was significantly associated with OS, LRFS, DMFS, and PFS (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt;\u00a00.05). In multivariate models, neither MHD, MLD, nor MBD was significantly associated with survival outcomes, regardless of the inclusion of EDRIC; however, EDRIC demonstrated a significant correlation. For OS discrimination, Harrell\u2019s C-index reached 0.622 for the EDRIC-alone model, 0.734 for the model integrating clinical covariates and CBC markers, and 0.740 for the combined model incorporating clinical features, serial CBC indices and EDRIC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>EDRIC is an independent prognostic biomarker for OS, LRFS, PFS and DMFS in LA-NSCLC patients undergoing definitive thoracic (chemo)radiotherapy. Week 3 PLR also independently predicts all four survival endpoints. Compared with the EDRIC-only model, the integrated model incorporating pretreatment EDRIC, clinical variables, and on-treatment inflammatory markers (NLR and PLR) yields more accurate and comprehensive prognostic stratification for patients with LA-NSCLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1852238","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:44:47Z","timestamp":1787118287000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Study on the effects of estimated dose of radiation to immune cells and CBC parameters on the prognosis of patients with locally advanced non-small cell lung cancer undergoing radiotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Aihui","family":"Feng","sequence":"first","affiliation":[{"name":"Shanghai Chest Hospital , Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuyan","family":"Xia","sequence":"additional","affiliation":[{"name":"Shanghai Chest Hospital , Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Shao","sequence":"additional","affiliation":[{"name":"Shanghai Chest Hospital , Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[{"name":"Shanghai Chest Hospital , Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[{"name":"Shanghai Chest Hospital , Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengle","family":"Gu","sequence":"additional","affiliation":[{"name":"Shanghai Chest Hospital , Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Duan","sequence":"additional","affiliation":[{"name":"Shanghai Chest Hospital , Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[{"name":"Shanghai Chest Hospital , Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjiong","family":"Shen","sequence":"additional","affiliation":[{"name":"Shanghai Chest Hospital , Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaou","family":"Chen","sequence":"additional","affiliation":[{"name":"Shanghai Chest Hospital , Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Xu","sequence":"additional","affiliation":[{"name":"Shanghai Chest Hospital , Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2026.106070","article-title":"Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC","volume":"11","author":"Girard","year":"2026","journal-title":"ESMO Open"},{"key":"B5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41419-023-06211-2","article-title":"Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1771355","article-title":"Synergistic effects of radiotherapy and immunotherapy: improving oncological outcomes","volume":"17","author":"Chen","year":"2026","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-206870","article-title":"Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment","volume":"114","author":"Lee","year":"2009","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-0037","article-title":"Toward precision radiotherapy for use with immune checkpoint blockers","volume":"24","author":"Vanpouille-Box","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3109\/07357907.2013.767342","article-title":"Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer","volume":"31","author":"Campian","year":"2013","journal-title":"Cancer Invest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-3888-y","article-title":"Radiation-related lymphopenia as a new prognostic factor in limited-stage small cell lung cancer","volume":"37","author":"Cho","year":"2016","journal-title":"Tumour Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.09.010","article-title":"The impact of radiation therapy on lymphocyte count and survival in metastatic cancer patients receiving PD-1 immune checkpoint inhibitors","volume":"103","author":"Pike","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2021.03.026","article-title":"Is a higher estimated dose of radiation to immune cells predictive of survival in patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy","volume":"159","author":"Yin","year":"2021","journal-title":"Radiother Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109804","article-title":"Impact of radiation dose to the immune system on disease progression and survival for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy","volume":"186","author":"Wang","year":"2023","journal-title":"Radiother Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246193","article-title":"Higher radiation dose to the immune cells correlates with worse tumor control and overall survival in patients with stage III NSCLC: a secondary analysis of RTOG0617","volume":"13","author":"Jin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)71207-0","article-title":"Standard-dose versus highdose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/j.ijrobp.2017.06.250","article-title":"Long-term results of RTOG 0617: a randomized phase 3 comparison of standard dose versus high dose conformal chemoradiation therapy \u00fe\/- cetuximab for stage III NSCLC","volume":"99","author":"Bradley","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.04.025","article-title":"Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes","volume":"89","author":"Tang","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.05.064","article-title":"Impact of radiation dose to the host immune system on tumor control and survival for stage III non-small cell lung cancer treated with definitive radiation therapy","volume":"105","author":"Ladbury","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B20","volume-title":"R: A Language and Environment for Statistical Computing","year":"2025"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101366","article-title":"Radiotherapy: brightness and darkness in the era of immunotherapy","volume":"19","author":"Zhai","year":"2022","journal-title":"Transl Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.08.047","article-title":"Impact of treatment-related lymphopenia on immunotherapy for advanced non-small cell lung cancer","volume":"105","author":"Cho","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2019.02.009","article-title":"Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1\/PD-L1 inhibitors","volume":"130","author":"Jiang","year":"2019","journal-title":"Lung Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s199176","article-title":"Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB)","volume":"12","author":"Ren","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.979384","article-title":"Hypofractionated concurrent chemoradiotherapy related lymphopenia and its association with survival in locally advanced non-small cell lung cancer patients","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152593","article-title":"Neutrophil dynamics in response to cancer therapies","volume":"17","author":"Xu","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab","volume":"111","author":"Diem","year":"2017","journal-title":"Lung Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1186\/s12885-025-14060-9","article-title":"Peripheral blood inflammatory biomarkers neutrophil\/ lymphocyte ratio, platelet\/lymphocyte ratio and systemic immune-inflammation index\/albumin ratio predict prognosis and efficacy in non-small cell lung cancer patients receiving immunotherapy and opioids","volume":"25","author":"Lei","year":"2025","journal-title":"BMC Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-666","article-title":"Pre-radiotherapy lymphocyte count and platelet-to-lymphocyte ratio may improve survival prediction beyond clinical factors in limited stage small cell lung cancer: model development and validation","volume":"9","author":"Yu","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.09.049","article-title":"A multi-institutional comparative analysis of proton and photon therapyinduced hematologic toxicity in patients with medulloblastoma","volume":"109","author":"Liu","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.12.019","article-title":"Proton beam therapy reduces the risk of severe radiation-induced lymphopenia during chemoradiotherapy for locally advanced non-small cell lung cancer: a comparative analysis of proton versus photon therapy","volume":"156","author":"Kim","year":"2021","journal-title":"Radiother Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063366","article-title":"Radiobiological and treatment-related aspects of spatially fractionated radiotherapy","volume":"23","author":"Moghaddasi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1178681","article-title":"Inhomogeneously distributed ferroptosis with a high peak-to-valley ratio may improve the antitumor immune response","volume":"13","author":"Chi","year":"2023","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.3997","article-title":"Changes in systemic immune response after stereotactic ablative radiotherapy. Preliminary results of a prospective study in patients with early lung cancer","volume":"127","author":"Rutkowski","year":"2017","journal-title":"Pol Arch Intern Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/ac16ea","article-title":"HEDOS-a computational tool to assess radiation dose to circulating blood cells during external beam radiotherapy based on whole-body blood flow simulations","volume":"66","author":"Shin","year":"2021","journal-title":"Phys Med Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1852238\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:44:48Z","timestamp":1787118288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1852238\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2026.1852238"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1852238","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1852238"}}